Who Has Lost Weight on Ozempic? Exploring Celebrity Experiences and Insights

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a powerful tool for sustainable weight loss, with clinical trials demonstrating an average 15-22% body weight reduction over 68 weeks. Beyond celebrity endorsements, the medication works by regulating hunger signals in the brain and slowing gastric emptying, creating a physiological foundation for lasting results. PlexusDx delivers pharmaceutical-grade compounded semaglutide injections from licensed 503A compounding pharmacies, making personalized GLP-1 therapy accessible across all 50 states.

How Semaglutide Produces Measurable Weight Loss Results

Semaglutide mimics the natural GLP-1 hormone, which signals satiety to the hypothalamus and reduces appetite-driven eating behaviors. When patients receive semaglutide therapy, they experience genuine reductions in food cravings and portion sizes without relying solely on willpower or restrictive dieting. The medication also improves metabolic efficiency by enhancing pancreatic insulin secretion when blood glucose rises, supporting stable energy levels throughout the day.

Real-world data from semaglutide users shows that weight loss typically begins within 2-4 weeks of starting treatment, with progressive results continuing through months 4-6 as the body adapts to the medication. Most individuals maintain consistency in weight loss when combined with modest dietary adjustments and regular movement, rather than extreme caloric restriction. PlexusDx patients using compounded semaglutide injections report similar outcomes to brand-name formulations, at a fraction of the cost.

Clinical Evidence Behind Semaglutide's Effectiveness

The STEP trial program, which enrolled over 4,500 participants with obesity, demonstrated that semaglutide at the 2.4 mg maintenance dose produced mean weight loss of 15.3 kg compared to 2.6 kg in the placebo group over 68 weeks. Participants also experienced improvements in cardiovascular risk markers, including lower blood pressure and reduced triglycerides, supporting benefits beyond weight reduction alone. These findings established semaglutide as a clinically validated intervention rather than a temporary trend.

Secondary analyses revealed that semaglutide's effects persist when patients continue treatment consistently, with weight regain occurring primarily if the medication is discontinued without lifestyle modifications in place. Age, baseline weight, and metabolic factors influence individual response rates, which is why genetic insights through testing—such as PlexusDx's Precision Peptide Genetic Test—help identify who may respond optimally to semaglutide versus alternative GLP-1 compounds like tirzepatide.

Why Semaglutide Has Become the Preferred Weight Loss Medication

Semaglutide's popularity stems from its favorable safety profile, once-weekly injection convenience, and predictable dose escalation schedule that minimizes side effects during titration. Unlike some weight loss approaches that require daily multiple dosing or significant behavioral overhaul, semaglutide integrates into most lifestyles with minimal disruption. The medication also addresses underlying metabolic dysfunction rather than creating artificial energy deficits that often trigger rebound weight gain.

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan, with the pricing commitment that your dose may increase, but your price won't remain flat across all three membership tiers. This transparent approach removes the financial uncertainty many patients face when titrating weight loss medications, making long-term commitment more feasible for those without insurance coverage.

Accessing Semaglutide Through PlexusDx: Affordability and Convenience

PlexusDx delivers pharmaceutical-grade compounded semaglutide injections from licensed 503A compounding pharmacies to all 50 states, eliminating geographic barriers and insurance requirements that traditionally limit access to GLP-1 therapy. The treatment is $189/mo month-to-month, or from $149/mo on the 6-month plan, with HSA and FSA eligibility providing additional savings opportunities for patients managing expenses. Medical supervision is integrated, ensuring dosing adjustments align with individual tolerance and weight loss goals.

Patients interested in understanding their unique metabolic response can add the Precision Peptide Genetic Test ($298) to identify how their genetic variants in GIPR and FTO, and MC4R pathways influence semaglutide response. This personalization approach helps determine whether semaglutide alone or combination therapy (such as GLP-Squared, which pairs semaglutide with tirzepatide) may optimize outcomes for each individual.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose using semaglutide?

Clinical trials show average weight loss of 15-22% of body weight over 68 weeks with semaglutide monotherapy. Individual results vary based on baseline weight, adherence, lifestyle factors, and genetic predisposition—areas the PlexusDx Precision Peptide Genetic Test can clarify. Most patients experience steady progress during the first 6 months, followed by plateau phases that reflect metabolic adaptation rather than treatment failure.

Is compounded semaglutide from PlexusDx as effective as brand-name Ozempic?

PlexusDx compounded semaglutide is manufactured in licensed 503A compounding pharmacies using pharmaceutical-grade ingredients identical in chemical structure to brand formulations. Real-world outcomes match clinical trial data, with patients experiencing comparable weight loss and metabolic improvements. The primary difference is cost—PlexusDx is $189 monthly month-to-month versus significantly higher brand-name pricing without insurance.

What is the cost difference between PlexusDx semaglutide and other GLP-1 options?

PlexusDx compounded semaglutide injection is $189/mo month-to-month, or from $149/mo on the 6-month plan (flat across all dose levels), while oral semaglutide is $289/mo month-to-month (or $249/mo on the 6-month plan) and dual-compound GLP-Squared injection is $289/mo month-to-month, or from $249/mo on the 3-month plan. All prices remain fixed regardless of dose escalation, ensuring predictable long-term costs. HSA and FSA eligibility further reduces out-of-pocket expenses for eligible patients across all states.

What side effects should I expect when starting semaglutide?

Early side effects commonly include mild nausea, modest appetite reduction (the intended effect), and occasional GI changes that typically resolve within 1-2 weeks as the body adjusts. Serious adverse events are rare at prescribed doses, though patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia should discuss alternatives with their healthcare provider. PlexusDx medical supervision monitors tolerance throughout treatment.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's Precision Peptide Genetic Test ($298) analyzes 14 peptide pathways and 150+ genetic insights, including variants in GIPR and FTO, and MC4R that influence GLP-1 sensitivity and metabolic response. While genetics alone do not determine outcomes, this testing helps identify whether semaglutide monotherapy or alternative compounds like tirzepatide may align better with your individual biology, optimizing treatment selection from the start.

Related Reading

• Ozempic For Losing Weight
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.